Eugen F. Mesaros*, Benjamin J. Dugan, Min Gao, Muhammad Sheraz, Kayleigh McGovern-Gooch, Fran Xu, Kristi Yi Fan, Duyan Nguyen, Steven G. Kultgen, Aaron Lindstrom, Kim Stever, Breanna Tercero, Randall J. Binder, Fei Liu, Holly M. Micolochick Steuer, Nagraj Mani, Troy O. Harasym, Emily P. Thi, Andrea Cuconati, Bruce D. Dorsey, Andrew G. Cole, Angela M. Lam and Michael J. Sofia,
{"title":"发现对 SARS-CoV-2 具有抗病毒活性的 C 链核苷类似物","authors":"Eugen F. Mesaros*, Benjamin J. Dugan, Min Gao, Muhammad Sheraz, Kayleigh McGovern-Gooch, Fran Xu, Kristi Yi Fan, Duyan Nguyen, Steven G. Kultgen, Aaron Lindstrom, Kim Stever, Breanna Tercero, Randall J. Binder, Fei Liu, Holly M. Micolochick Steuer, Nagraj Mani, Troy O. Harasym, Emily P. Thi, Andrea Cuconati, Bruce D. Dorsey, Andrew G. Cole, Angela M. Lam and Michael J. Sofia, ","doi":"10.1021/acsinfecdis.4c00122","DOIUrl":null,"url":null,"abstract":"<p >The recent COVID-19 pandemic underscored the limitations of currently available direct-acting antiviral treatments against acute respiratory RNA-viral infections and stimulated major research initiatives targeting anticoronavirus agents. Two novel nsp5 protease (MPro) inhibitors have been approved, nirmatrelvir and ensitrelvir, along with two existing nucleos(t)ide analogues repurposed as nsp12 polymerase inhibitors, remdesivir and molnupiravir, but a need still exists for therapies with improved potency and systemic exposure with oral dosing, better metabolic stability, and reduced resistance and toxicity risks. Herein, we summarize our research toward identifying nsp12 inhibitors that led to nucleoside analogues <b>10e</b> and <b>10n</b>, which showed favorable pan-coronavirus activity in cell-infection screens, were metabolized to active triphosphate nucleotides in cell-incubation studies, and demonstrated target (nsp12) engagement in biochemical assays.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2\",\"authors\":\"Eugen F. Mesaros*, Benjamin J. Dugan, Min Gao, Muhammad Sheraz, Kayleigh McGovern-Gooch, Fran Xu, Kristi Yi Fan, Duyan Nguyen, Steven G. Kultgen, Aaron Lindstrom, Kim Stever, Breanna Tercero, Randall J. Binder, Fei Liu, Holly M. Micolochick Steuer, Nagraj Mani, Troy O. Harasym, Emily P. Thi, Andrea Cuconati, Bruce D. Dorsey, Andrew G. Cole, Angela M. Lam and Michael J. Sofia, \",\"doi\":\"10.1021/acsinfecdis.4c00122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The recent COVID-19 pandemic underscored the limitations of currently available direct-acting antiviral treatments against acute respiratory RNA-viral infections and stimulated major research initiatives targeting anticoronavirus agents. Two novel nsp5 protease (MPro) inhibitors have been approved, nirmatrelvir and ensitrelvir, along with two existing nucleos(t)ide analogues repurposed as nsp12 polymerase inhibitors, remdesivir and molnupiravir, but a need still exists for therapies with improved potency and systemic exposure with oral dosing, better metabolic stability, and reduced resistance and toxicity risks. Herein, we summarize our research toward identifying nsp12 inhibitors that led to nucleoside analogues <b>10e</b> and <b>10n</b>, which showed favorable pan-coronavirus activity in cell-infection screens, were metabolized to active triphosphate nucleotides in cell-incubation studies, and demonstrated target (nsp12) engagement in biochemical assays.</p>\",\"PeriodicalId\":17,\"journal\":{\"name\":\"ACS Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00122\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00122","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2
The recent COVID-19 pandemic underscored the limitations of currently available direct-acting antiviral treatments against acute respiratory RNA-viral infections and stimulated major research initiatives targeting anticoronavirus agents. Two novel nsp5 protease (MPro) inhibitors have been approved, nirmatrelvir and ensitrelvir, along with two existing nucleos(t)ide analogues repurposed as nsp12 polymerase inhibitors, remdesivir and molnupiravir, but a need still exists for therapies with improved potency and systemic exposure with oral dosing, better metabolic stability, and reduced resistance and toxicity risks. Herein, we summarize our research toward identifying nsp12 inhibitors that led to nucleoside analogues 10e and 10n, which showed favorable pan-coronavirus activity in cell-infection screens, were metabolized to active triphosphate nucleotides in cell-incubation studies, and demonstrated target (nsp12) engagement in biochemical assays.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.